Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Vaccine manufacturing is lumpy, supply not as good as hoped, UK says

Mon, 18th Jan 2021 08:16

* UK says AstraZeneca slower than hoped

* UK says Pfizer changes may lead to delays

* UK is vaccinating 140 people per minute on average
(Recasts headline and lead with manufacturing issues)

By Guy Faulconbridge and Kate Holton

LONDON, Jan 18 (Reuters) - Britain's vaccine rollout is
limited by a "lumpy" manufacturing process with production
changes by Pfizer and a delay by AstraZeneca
that could lead to brief supply disruption, Vaccine Deployment
Minister Nadhim Zahawi said on Monday.

The United Kingdom, which has the world's fifth worst
official COVID-19 death toll, is racing to be among the first
major countries to vaccinate its population - seen as the best
way to exit the pandemic and get the economy going again.

The United Kingdom has vaccinated 3,857,266 people with a
first dose and 449,736 with a second dose. On vaccines
administered per 100 people, the United Kingdom is fourth in the
world after Israel, the United Arab Emirates and Bahrain.

Zahawi told LBC radio that the United Kingdom was hoping for
2 million vaccines a week from AstraZeneca but that
those numbers will not be reached until mid February. Still, he
said the UK was on course to hit its rollout targets.

"It's been a bit lumpy," Zahawi said of vaccine manufacture.

Pfizer will temporarily reduce its deliveries to Europe of
its vaccine against COVID-19 while it upgrades its production
capacity.

"There's bound to be delays. Any new manufacturing process
has challenges at the outset, it is lumpy, it begins to
stabilise and get better and better week in, week out," Zahawi
told the BBC.

"The Pfizer BioNTech vaccine is a messenger RNA chemical,
difficult chemical to manufacture, very very challenging but
they're doing really well, they want to do more which is why
they're reconfiguring to add volume to the whole world," Zahawi
said.

"That could delay supply but I'm confident we can meet our
target."

VACCINE HOPES

Mass COVID-19 vaccines are seen as the best way to exit the
pandemic which has killed more than 2 million people, wiped out
trillions of dollars in economic output and upended normal life
for people across the world.

The United Kingdom is vaccinating 140 people per minute
against COVID-19 on average.

"It is going well, we're vaccinating on average 140 people,
that's first jab, literally a minute. That's the average so some
areas are doing better," Zahawi told Sky.

Britain is currently rolling out the vaccine to the most
vulnerable first, starting with those who are in care homes or
over 80 years of age. In areas where a majority of over 80s have
been offered a vaccine, letters are going out to the over 70s
and those who are clinically extremely vulnerable.

Zahawi said a 24-hour vaccine offering would begin to be
piloted in London by the end of the month.

Essential workers such as teachers, the police and shop
assistants could move to the top of the list for a vaccine once
all those over 50 have been offered a shot, Zahawi said.

"Teachers, police officers, shop workers, those who through
no fault of their own other than the work that they do may come
into contact with the virus in much greater volume, should be
top of the list," Zahawi told Times Radio.
(Reporting by Guy Faulconbridge and Kate Holton; editing by
Sarah Young, Paul Sandle and Philippa Fletcher)

More News
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.